

## Joint Working Executive Summary

<b>Joint working partners</b>	Cardiff and Vale University Health Board (CAVUHB), Recordati Pharmaceutical Ltd and three other pharmaceutical companies
<b>Project period</b>	30 months
<b>Project name</b>	Cardiff and Vale Post Coronary Revascularisation Lipid Optimisation Service
<b>Joint working project summary</b>	<p>The Project aims to establish a comprehensive post-acute coronary syndrome (ACS) lipid optimisation service for patients who have undergone a revascularisation procedure (acute or planned) within CAVUHB. The Service aims to improve patient outcomes and reduce the risk of future cardiovascular events and to reduce health care disparity and inequalities by ensuring the service is available to all patients who present to CAVUHB with ACS.</p> <p>The service will provide a rehabilitation and medicines optimization service for post-ACS patients, primarily those who have experienced an acute MI and are undergoing revascularisation procedures. Due to the diverse nature of post-ACS conditions, the clinic will be available to all patients' post-revascularisation, whether acute or planned, ensuring that everyone who could benefit from a review is given the opportunity for assessment.</p> <p><b>Recordati contact:</b> Ben Cook – National Partnerships Manager.  <b>Email:</b> ben.cook@recordati.com</p>
<b>Expected outcomes</b>	<p><b><u>Patients</u></b></p> <ul style="list-style-type: none"> <li>• Reduced risk of further cardiovascular events by improved adherence to post ACS guidelines and targets</li> <li>• Initiation and monitoring of appropriate lipid-lowering therapies</li> <li>• Improved adherence to 3-month follow-up</li> <li>• Designated point of contact post coronary revascularisation</li> <li>• Access to nurse prescriber leading to reduced wait for treatment</li> <li>• Health education and support</li> <li>• Access to genetic lipid testing for identification of FH and other genetic lipid conditions</li> <li>• Reduction in health inequalities</li> </ul>

## Joint Working Executive Summary

	<p><b><u>NHS and CVUHB</u></b></p> <ul style="list-style-type: none"><li>• Improved adherence to guidelines for lowering lipids post-ACS</li><li>• Identification of patients at risk of FH</li><li>• Identification of other genetic lipid conditions</li><li>• Cost benefit associated with reduction in admissions because of reduced recurrent cardiac events.</li><li>• Dedicated post-coronary revascularisation lipid optimisation service with a clear role within the cardiology service.</li><li>• Increased use of lipid-lowering therapies in line with their licenses</li></ul> <p><b><u>Recordati Pharmaceuticals Limited</u></b></p> <ul style="list-style-type: none"><li>• Better understanding of overall customers' and patients' needs.</li><li>• Optimal use of medicines, aligned to national and / or local guidelines (including Recordati medicines) in appropriate patients.</li><li>• Increased insight into post ACS patient pathway</li></ul>
<b>Project timeframe</b>	Project commenced July 2025
<b>Resource contribution</b>	Recordati are making a financial contribution of ¼ of the project costs an amount equal £124,600 Cardiff & Vale University Health Board are indirectly contributing £156,337